Genomic Vision announced that it has entered into a licensing agreement with European Equity Partners (EEP), a U.K private investment firm focused on life science investments, to use molecular combing technology within the bioprocessing domain. Pursuant to this agreement, the parties will enter into a period during which they will confirm that the Combing Genome Integrity assay can replace or complete existing quality control test in Bioprocessing. Followed a conclusive development program the two parties plan to establish of a new entity dedicated to applications of the Combing Genome Integrity assay in Biomanufacturing. This entity will have an exclusive license to Genomic Vision’s proprietary Molecular Combing technology in the field of Biomanufacturing. The new company will offer a mixed model of analytical services as well as license agreements to strategic partners using Genome Integrity Assay for the production of biological products such as therapeutic proteins, monoclonal or polyclonal antibodies, vaccines and viral particles. In exchange of the license right, Genomic Vision will receive an upfront, milestones payments (amounting to a total of more than €500 k) as well as royalties on sales and services.